CARMEL, Ind., May 2, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today it has presented the nonprofit organization Overdose Lifeline with the inaugural Syra Health Mental and Behavioral Health Solutions Award.

An independent psychiatrist, Dr. Bethany Richards, who oversaw the selection process, said Overdose Lifeline was chosen based on the award criteria. "Overdose Lifeline is an established advocacy group that offers education and resources on substance abuse to diverse communities. The organization focuses particularly on combating the opioid crisis, as well as utilizing social media platforms to promote the destigmatization of mental health issues."

According to the National Institute of Mental Health, Substance Use Disorder (SUD) is a treatable mental disorder that affects a person's brain and behavior, leading to their inability to control their use of substances like legal or illegal drugs, alcohol, or medications. Symptoms can be moderate to severe with addiction being the most severe form of SUD. People with SUD may also have other mental health disorders, such as anxiety, or depression.

"We were proud to present the inaugural Syra Health Mental and Behavioral Health Solutions Award to Overdose Lifeline," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "There are gaps in mental health treatment that can only be filled by advocacy groups like Overdose Lifeline in collaboration with companies like ours that are focused on the technology interventions, while always keeping the individual suffering at the heart of our solutions."

Syra Health presented the inaugural Syra Health Mental and Behavioral Health Solutions Award during Syra's Mental Health Solutions Day, showcasing solutions to the mental health crisis in America. Syra Health expects to host the event and present its award on an annual basis.

ABOUT SYRA HEALTH

Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.

FORWARD-LOOKING STATEMENTS

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.

For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.